SPOTLIGHT -
HSD3B1 CC genotype associated with inferior outcomes in prostate cancer
"Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality,” says Nima Sharifi, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
340B program linked to improved prostate cancer treatment adherence
"We suspect that 340B hospitals potentially have some resources or mechanisms that are helping these vulnerable patients maintain adherence,” says Kassem S. Faraj, MD.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Trial begins of NUV-1511 in solid tumors, including mCRPC
Overall, the phase 1/2 trial is designed to explore the safety, tolerability, pharmacokinetics, and preliminary clinical activity of NUV-1511 in patients with advanced solid tumors.
The dilemma of using disposable scopes
"I am still struggling with disposing the scopes after each use, both from the environmental aspect and the fact that the scope technically can be used more than once," writes Gopal H. Badlani, MD.